newsfilter
← Latest News
Business Wire·

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation